O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+7.9%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$3.98B
AUM Growth
+$3.98B
(-4.5%)
Cap. Flow
-$356M
Cap. Flow
% of AUM
-8.96%
Top 10 Holdings %
Top 10 Hldgs %
49.18%
Holding
122
New
13
Increased
19
Reduced
24
Closed
22
Top Buys
| 1 |
CAI
Caris Life Sciences, Inc. Common Stock
CAI
|
$81.1M |
| 2 |
UnitedHealth
UNH
|
$42.1M |
| 3 |
Roivant Sciences
ROIV
|
$31.3M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
$22.4M |
| 5 |
CytomX Therapeutics
CTMX
|
$19.2M |
Top Sells
| 1 |
Pfizer
PFE
|
$97.6M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$76.6M |
| 3 |
Neurocrine Biosciences
NBIX
|
$62.4M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
$41.9M |
| 5 |
Xtant Medical Holdings
XTNT
|
$34.4M |
Sector Composition
| 1 | Healthcare | 99.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MBX
26
MBX Biosciences, Inc. Common Stock
MBX
$484M
| $45.7M | 1.14% |
4,002,887
| – | – |
|
27
Axsome Therapeutics
AXSM
$6.09B
| $44.7M | 1.12% |
427,900
+41,200
| +11% | +$4.3M |
|
28
Compass Therapeutics
CMPX
$466M
| $39.6M | 0.99% |
15,219,994
-7,142,856
| -32% | -$18.6M |
|
29
Cytokinetics
CYTK
$5.98B
| $35.6M | 0.89% |
1,077,000
-432,205
| -29% | -$14.3M |
|
30
Crinetics Pharmaceuticals
CRNX
$3.26B
| $33M | 0.83% |
1,149,000
+150,000
| +15% | +$4.31M |
|
31
Exact Sciences
EXAS
$9.33B
| $32.3M | 0.81% |
607,316
-72,500
| -11% | -$3.85M |
|
|
THRD
32
DELISTED
Third Harmonic Bio
THRD
| $31.4M | 0.78% |
5,779,071
| – | – |
|
|
33
Roivant Sciences
ROIV
$8.6B
| $31.3M | 0.78% |
+2,779,427
| New | +$31.3M |
|
34
Xenon Pharmaceuticals
XENE
$2.99B
| $29.7M | 0.74% |
947,877
| – | – |
|
35
Neuropace
NPCE
$310M
| $29.1M | 0.73% |
2,614,184
-792,151
| -23% | -$8.82M |
|
36
Corvus Pharmaceuticals
CRVS
$419M
| $28.7M | 0.72% |
7,165,006
+221,352
| +3% | +$885K |
|
37
Terns Pharmaceuticals
TERN
$651M
| $28.2M | 0.7% |
7,562,971
| – | – |
|
38
Janux Therapeutics
JANX
$1.38B
| $28M | 0.7% |
1,210,300
+451,734
| +60% | +$10.4M |
|
39
Apellis Pharmaceuticals
APLS
$3.51B
| $25.7M | 0.64% |
1,482,300
+50,000
| +3% | +$866K |
|
40
Structure Therapeutics
GPCR
$1.14B
| $24.9M | 0.62% |
1,199,300
+547,272
| +84% | +$11.4M |
|
41
scPharmaceuticals
SCPH
$296M
| $23.1M | 0.58% |
6,059,528
| – | – |
|
|
42
CytomX Therapeutics
CTMX
$350M
| $19.2M | 0.48% |
+8,461,500
| New | +$19.2M |
|
43
Thermo Fisher Scientific
TMO
$183B
| $18.9M | 0.47% |
46,500
-82,500
| -64% | -$33.5M |
|
44
Agios Pharmaceuticals
AGIO
$2.36B
| $18.6M | 0.46% |
557,900
+232,400
| +71% | +$7.73M |
|
45
Trevi Therapeutics
TRVI
$871M
| $18.1M | 0.45% |
3,308,400
+2,188,400
| +195% | +$12M |
|
46
ADC Therapeutics
ADCT
$370M
| $15.8M | 0.4% |
5,907,351
-61,100
| -1% | -$164K |
|
47
Rhythm Pharmaceuticals
RYTM
$6.75B
| $15.7M | 0.39% |
248,512
-131,488
| -35% | -$8.31M |
|
48
Forte Biosciences
FBRX
$138M
| $15.5M | 0.39% |
1,196,955
+603,867
| +102% | +$7.81M |
|
49
Cullinan Oncology
CGEM
$456M
| $14.5M | 0.36% |
1,923,855
| – | – |
|
50
Keros Therapeutics
KROS
$640M
| $13.6M | 0.34% |
1,018,734
| – | – |
|